Scholarlink

Introduction <p>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, significantly affects glucose and body weight-lowering effects in randomized controlled trials. However, real-world clinical evidence in Japan remains limited. This study aimed to evaluate the real-world effectiveness of tirzepatide on glycemic and metabolic factors in Japanese patients with type 2 diabetes mellitus (T2DM).</p> Methods <p>In this multicenter, retrospective, observational study, we included patients with T2DM from seven Japanese institutions who received tirzepatide treatment for at least 24 weeks. Tirzepatide effectiveness was evaluated by comparing clinical and biochemical parameters, including glycated hemoglobin (HbA1c), plasma glucose levels, body weight, blood pressure, lipid profiles, liver enzyme levels, and renal function, before and after 24 weeks of treatment.</p> Results <p>We included 324 patients (mean age, 56.8 ± 11.4 years; median body mass index (BMI), 30.4 kg/m<sup>2</sup> (interquartile range 26.8–34.0)). At 24 weeks, 42 (13.0%), 211 (65.1%), 35 (10.8%), 25 (7.7%), and 11 (3.4%) patients received 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 12.5/15 mg tirzepatide, respectively. HbA1c and body weight significantly decreased after tirzepatide administration; the median HbA1c and body weight reduced from 7.9% [7.2–8.6] to 6.8% [6.1–7.5] and from 82.5 kg [73.5–94.6] to 80.0 kg [70.9–92.5], respectively, whereas the medians of changes in HbA1c and body weight from baseline to week 24 were –&#xa0;0.9% [–&#xa0;1.6 to –&#xa0;0.3] and –&#xa0;2.0 kg [–&#xa0;4.0 to 0.0] (<i>p</i> &lt; 0.001). HbA1c reduction was greater in GLP-1 receptor agonist-naïve patients (<i>p</i> &lt; 0.001). Changes in HbA1c levels significantly correlated with baseline HbA1c levels (<i>r</i><sub>s</sub> = –&#xa0;0.473, <i>p</i> &lt; 0.001), but not BMI.</p> Conclusions <p>In real-world clinical practice, tirzepatide was associated with improvements in glycemic control and reductions in body weight in Japanese patients with T2DM, across diverse baseline therapies. These results suggest that tirzepatide may be a useful option across diverse treatment backgrounds, with greater observed benefits in GLP-1RA-naïve individuals with higher baseline HbA1c levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Noriyuki Takahashi,
  • Makoto Ohara,
  • Hiroki Yokoyama,
  • Hiroaki Seino,
  • Munenori Hiromura,
  • Shutaro Ozawa,
  • Takemasa Omachi,
  • Nobuaki Takehana,
  • Tomoki Fujikawa,
  • Ayako Ohara,
  • Shunichiro Irie,
  • Naoya Osaka,
  • Michishige Terasaki,
  • Aya Yoshihara,
  • Yusaku Mori,
  • Tomoyasu Fukui,
  • Sho-ichi Yamagishi

摘要

Introduction

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, significantly affects glucose and body weight-lowering effects in randomized controlled trials. However, real-world clinical evidence in Japan remains limited. This study aimed to evaluate the real-world effectiveness of tirzepatide on glycemic and metabolic factors in Japanese patients with type 2 diabetes mellitus (T2DM).

Methods

In this multicenter, retrospective, observational study, we included patients with T2DM from seven Japanese institutions who received tirzepatide treatment for at least 24 weeks. Tirzepatide effectiveness was evaluated by comparing clinical and biochemical parameters, including glycated hemoglobin (HbA1c), plasma glucose levels, body weight, blood pressure, lipid profiles, liver enzyme levels, and renal function, before and after 24 weeks of treatment.

Results

We included 324 patients (mean age, 56.8 ± 11.4 years; median body mass index (BMI), 30.4 kg/m2 (interquartile range 26.8–34.0)). At 24 weeks, 42 (13.0%), 211 (65.1%), 35 (10.8%), 25 (7.7%), and 11 (3.4%) patients received 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 12.5/15 mg tirzepatide, respectively. HbA1c and body weight significantly decreased after tirzepatide administration; the median HbA1c and body weight reduced from 7.9% [7.2–8.6] to 6.8% [6.1–7.5] and from 82.5 kg [73.5–94.6] to 80.0 kg [70.9–92.5], respectively, whereas the medians of changes in HbA1c and body weight from baseline to week 24 were – 0.9% [– 1.6 to – 0.3] and – 2.0 kg [– 4.0 to 0.0] (p < 0.001). HbA1c reduction was greater in GLP-1 receptor agonist-naïve patients (p < 0.001). Changes in HbA1c levels significantly correlated with baseline HbA1c levels (rs = – 0.473, p < 0.001), but not BMI.

Conclusions

In real-world clinical practice, tirzepatide was associated with improvements in glycemic control and reductions in body weight in Japanese patients with T2DM, across diverse baseline therapies. These results suggest that tirzepatide may be a useful option across diverse treatment backgrounds, with greater observed benefits in GLP-1RA-naïve individuals with higher baseline HbA1c levels.